To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC46202 | N3-PEG4-DYKDDDD-Doxorubicin |
N3-PEG4-DYKDDDD-Doxorubicin is a drug-linker conjugate for ADC with potent antitumor activity by using the cytotoxic anthracycline antibiotic, Doxorubicin, linked via the cleavable linker N3-PEG4-DYKDDDD.
More description
|
|
| DC46201 | MC-VC-PABC-SP 141 |
MC-VC-PABC-SP 141 is a drug-linker conjugate for ADC with potent antitumor activity by using SP 141 (a potent MDM2 inhibitor), linked via the cleavable ADC linker MC-VC-PABC.
More description
|
|
| DC46088 | Ozogamicin |
Ozogamicin is a drug-linker conjugates for ADC. Ozogamicin can used in the synthesis of gemtuzumab ozogamicin and inotuzumab ozogamicin.
More description
|
|
| DC46087 | MCC-DM1 |
MCC-DM1 is a drug-Linker Conjugates for ADC such ad Anti-CD22-MCC-DM1.
More description
|
|
| DC46006 | Modified MMAF-C5-COOH |
Modified MMAF-C5-COOH is a drug-linker conjugate for ADC.
More description
|
|
| DC45852 | Lys-Nε-SPDB-DM4 |
Lys-Nε-SPDB-DM4 is a drug-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody drug conjugate (ADC).
More description
|
|
| DC40468 | Mc-VC-PAB-SN38 Featured |
Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs).
More description
|
|
| DC40402 | MAC glucuronide α-hydroxy lactone-linked SN-38 |
MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a stabilized lactone MAC glucuronide α-hydroxy lactone-linked SN-38 drug linker. MAC glucuronide α-hydroxy lactone-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC50 values of 99 and 105 ng/mL, respectively.
More description
|
|
| DC28907 | MMAE-SMCC |
MMAE-SMCC is a drug-linker conjugate for ADC. MMAE-SMCC is composed of a potent mitotic and a tubulin inhibitor MMAE and a linker SMCC to make antibody drug conjugate.
More description
|
|
| DC28685 | Thalidomide-NH-PEG7 |
Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate for ADC. Thalidomide-NH-PEG7 can be connected to the ligand for protein by a linker to form PROTAC iRucaparib-AP6, a highly specific PARP1 degrader.
More description
|
|
| DC28510 | DBCO-PEG4-VC-PAB-DMEA-PNU-159682 |
DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for ADC, consists the ADC linker DBCO-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.
More description
|
|
| DC28509 | DBCO-(PEG2-VC-PAB-MMAE)2 |
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.
More description
|
|
| DC28508 | SC-VC-PAB-MMAE |
SC-VC-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB.
More description
|
|
